IRIS
ATZENI, Fabiola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.821
EU - Europa 8.355
AS - Asia 6.069
SA - Sud America 2.415
Continente sconosciuto - Info sul continente non disponibili 649
AF - Africa 221
OC - Oceania 11
Totale 27.541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.539
RU - Federazione Russa 5.016
SG - Singapore 2.689
BR - Brasile 2.056
CN - Cina 1.457
IE - Irlanda 1.242
HK - Hong Kong 724
SE - Svezia 638
IT - Italia 466
VN - Vietnam 313
FR - Francia 286
DE - Germania 197
IN - India 143
AR - Argentina 128
BD - Bangladesh 118
PL - Polonia 112
GB - Regno Unito 108
CA - Canada 89
IQ - Iraq 81
MX - Messico 78
ZA - Sudafrica 68
TR - Turchia 66
NL - Olanda 56
ID - Indonesia 48
EC - Ecuador 46
FI - Finlandia 46
UZ - Uzbekistan 46
VE - Venezuela 46
PK - Pakistan 44
JP - Giappone 42
CO - Colombia 36
AT - Austria 31
UA - Ucraina 30
MA - Marocco 28
EG - Egitto 27
CL - Cile 26
ES - Italia 26
PY - Paraguay 26
SA - Arabia Saudita 25
AE - Emirati Arabi Uniti 24
BE - Belgio 24
JO - Giordania 22
KE - Kenya 22
BO - Bolivia 21
CR - Costa Rica 20
JM - Giamaica 20
NP - Nepal 20
KZ - Kazakistan 18
PE - Perù 18
IL - Israele 17
AZ - Azerbaigian 16
DZ - Algeria 16
TN - Tunisia 16
PH - Filippine 15
IR - Iran 14
MY - Malesia 13
PA - Panama 13
KG - Kirghizistan 12
LB - Libano 11
OM - Oman 11
HN - Honduras 10
NI - Nicaragua 10
PS - Palestinian Territory 10
TH - Thailandia 10
UY - Uruguay 10
DO - Repubblica Dominicana 9
PT - Portogallo 9
QA - Qatar 9
SN - Senegal 9
GT - Guatemala 8
RO - Romania 8
SY - Repubblica araba siriana 8
AL - Albania 7
BY - Bielorussia 7
CI - Costa d'Avorio 7
ET - Etiopia 7
SV - El Salvador 7
TT - Trinidad e Tobago 7
AM - Armenia 6
CZ - Repubblica Ceca 6
EU - Europa 6
AO - Angola 5
AU - Australia 5
BH - Bahrain 5
CH - Svizzera 5
DK - Danimarca 5
GE - Georgia 5
KR - Corea 5
RS - Serbia 5
TW - Taiwan 4
BG - Bulgaria 3
CY - Cipro 3
GA - Gabon 3
GR - Grecia 3
LT - Lituania 3
MN - Mongolia 3
NG - Nigeria 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BN - Brunei Darussalam 2
Totale 26.848
Salva come PNG Salva come JPEG
Città #
Moscow 1.751
Singapore 1.540
Ashburn 1.360
Dublin 1.240
Chandler 1.009
Dallas 933
Hong Kong 713
Beijing 593
Nyköping 456
San Jose 408
Council Bluffs 357
New York 354
Princeton 271
Jacksonville 251
Dearborn 245
The Dalles 230
Medford 229
Lauterbourg 214
Des Moines 205
São Paulo 173
Los Angeles 170
Cambridge 166
Redondo Beach 116
Santa Clara 109
Buffalo 102
Ho Chi Minh City 102
Warsaw 100
Messina 96
Rio de Janeiro 85
Ann Arbor 74
Munich 70
Hanoi 69
Orem 62
Wilmington 61
Tianjin 60
Belo Horizonte 59
Frankfurt am Main 59
Pune 59
Guangzhou 51
Nanjing 43
Tashkent 42
Shenyang 40
Tokyo 39
Atlanta 38
Jinan 33
Baghdad 31
Brooklyn 31
Milan 31
Rome 31
Nuremberg 30
San Francisco 30
Seattle 30
Brasília 28
Chicago 28
Johannesburg 28
Porto Alegre 28
Buenos Aires 26
Montreal 26
Phoenix 26
Amsterdam 25
London 25
Campinas 24
Boardman 23
Shanghai 23
Chennai 22
Mexico City 22
Falls Church 21
Turku 21
Brussels 20
Curitiba 20
Salvador 20
Catania 19
Columbus 19
Denver 19
Dhaka 19
Ningbo 19
San Mateo 19
Amman 18
Haikou 18
Hebei 18
Nairobi 18
Cape Town 17
Fortaleza 17
Vienna 17
Zhengzhou 17
Caxias do Sul 16
Guarulhos 16
Norwalk 16
Changsha 15
Guayaquil 15
Haiphong 15
Hangzhou 15
Houston 15
Istanbul 15
Quito 15
Washington 15
Aracaju 14
Baku 14
Caracas 14
Dong Ket 14
Totale 15.585
Salva come PNG Salva come JPEG
Nome #
EULAR revised recommendations for the management of fibromyalgia 308
International, multidisciplinary Delphi consensus recommendations on non-pharmacological interventions for fibromyalgia 224
CORRELATION BETWEEN DISEASE ACTIVITY AND CARDIOVASCULAR PARAMETERS IN PATIENTS WITH ANKYLOSING SPONDYLITIS 200
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors 194
CARDIOVASCULAR EVALUATION USING NON-INVASIVE IMAGING METHODS IN PATIENTS WITH ANKYLOSING SPONDYLITIS BEFORE AND AFTER 12 MONTHS OF TREATMENT WITH ANTI-TNF DRUGS 190
A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data 188
Algo-dysfunctional syndromes: a critical digest of the recent literature 186
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis 185
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases 180
Certainties and uncertainties concerning the contribution of pericytes to the pathogenesis of systemic sclerosis 176
Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases 175
Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents 171
Biomarkers in Rheumatoid Arthritis 164
BODY MASS INDEX, SMOKING STATUS AND RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS: A REAL-LIFE STUDY. 162
Comparison of Efficacy of Ketoprofen and Ibuprofen in Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis 159
A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac 158
Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis 157
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: A case series 153
CLINICAL AND ULTRASONOGRAPHIC EVALUATION IN A COHORT OF SUSTAINED REMISSION RHEUMATOID ARTHRITIS PATIENTS AFTER STOPPING BIOLOGIC THERAPY: A SINGLE CENTER EXPERIENCE , 151
Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound 151
Recurrent intracranial hemorrhage and cerebral venous sinus thrombosis: an atypical case of Neuro-Behçet’s Syndrome 150
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study 149
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study 141
RELATIONSHIP BETWEEN ULTRASONOGRAPHIC SALIVARY GLANDS ABNORMALITIES AND SUBCLINICAL CARDIOVASCULAR INVOLVEMENT IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME 140
A proteinuria cut-off level of 0.7 g /day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial 139
B Lymphocyte intestinal homing in inflammatory bowel disease 138
Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports 137
A possible link between ankylosing spondylitis and periodontitis: A systematic review and meta-analysis 135
An update on emerging drugs for fibromyalgia treatment 135
The microbiome in connective tissue diseases and vasculitides: An updated narrative review 130
A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis 129
The neuropathic pain features in Psoriatic Arthritis: a cross-sectional evaluation of prevalence and associated factors 129
Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria? 128
Biological agents in rheumatoid arthritis: A cross-link between immune tolerance and immune surveillance 128
MEASUREMENT OF SERUM ALPHA-KLOTHO IN SYSTEMIC SCLEROSIS PATIENTS: RESULTS FROM A PIVOTAL STUDY. 127
Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain 126
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab 126
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis 125
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients 122
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry 120
From autoinflammation to autoimmunity: old and recent findings 120
One year in review 2019: fibromyalgia 119
Systemic rheumatic diseases: from biological agents to small molecules 119
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis 118
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents 117
Measuring psoriatic disease in clinical practice. An expert opinion position paper 115
Safety of Abatacept in Rheumatoid Arthritis with Serologic Evidence of Past or Present Hepatitis B Virus Infection 113
Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response 113
Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review 113
Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical trial 112
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA Registry: An appraisal of predictors 111
Immunogenicity and autoimmunity during anti-TNF therapy 111
Ultrasonographyc Evaluation of Metacarpophalangeal Joints Can be Useful in the Differential Diagnosis of Early Rheumatoid Arthritis and Early Spondyloarthritis. A Monocentric Preliminary Study 111
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. 111
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 111
PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease 110
Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment 109
Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: An assessment of combined tests 109
Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma? 108
Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study 108
Impaired lung transfer factor in fibromyalgia syndrome 108
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? 108
CC chemokine receptor 5 polymorphism in Italian patients with Beḩet's disease 107
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment 107
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: Real-life data from the LORHEN registry 106
Chronic widespread pain in the spectrum of rheumatological diseases 106
What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis? 105
Psoriatic arthritis: From pathogenesis to pharmacologic management 105
Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study 104
Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register 103
Pain in systemic sclerosis 103
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project) 103
EULAR recommendations for management of fibromyalgia 103
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric 103
Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data 103
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update 102
Measurement of Serum Klotho in Systemic Sclerosis 102
Differential Diagnosis of Vasovagal Syncope: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 102
Patients Failing to Fulfill 2016 Criteria for Fibromyalgia Represent a Truly Different Population Subset 102
Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study 102
DOSE REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RESPONDING TO THE STANDARD RITUXIMAB REGIMEN. 100
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry 100
Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial 98
AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS) 98
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort 98
Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography 98
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks 97
Infections and Biological Therapy in Patients with Rheumatic Diseases 97
Web/Internet-based telemonitoring of a randomized controlled trial evaluating the time-integrated effects of a 24-week multicomponent intervention on key health outcomes in patients with fibromyalgia 97
The effect of drugs used in rheumatology for treating SARS-CoV2 infection 96
Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases 96
PREVALENCE OF CHRONIC WIDESPREAD PAIN IN SSC PATIENTS: PRELIMINARY DATA 96
Laboratory monitoring of biological therapies in rheumatology: The role of immunogenicity 96
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 96
SDAI AS PREDICTOR OF 1-YEAR EFFICACY OF THE FIRST TNF BLOCKER IN CLINICAL PRACTICE. 95
Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia 94
Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis 94
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: A cross-sectional study from the Big Data Sjögren’s Project Consortium 94
Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia 93
Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases 92
Totale 12.553
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.721
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.721
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.170 0 60 3 30 96 21 27 51 36 55 169 622
2022/20233.443 311 221 155 315 169 347 19 199 1.556 14 110 27
2023/20241.113 94 133 188 83 69 383 7 33 4 32 7 80
2024/20254.812 74 44 93 294 148 152 146 1.060 1.340 335 395 731
2025/202613.263 484 947 1.149 759 1.131 3.036 1.653 1.444 1.375 634 258 393
2026/20271.526 537 989 0 0 0 0 0 0 0 0 0 0
Totale 27.541